Liver International · 2024 · 19 citations · 13 references
MedicineOncologyPharmacotherapyChemotherapyMedical OncologyOncology PharmacotherapyHepatobiliary CancerHepatocellular CarcinomaHepatocellular Carcinoma PharmacotherapyLiver CancerAtezolizumab TherapyCombination TherapyComplete Response AssessmentHepatic MalignancyHepatobiliary Cancer Systemic TherapyHepatocellular Carcinoma TreatmentLiver Tumor Therapy
BACKGROUND: To identify predictive factors associated with successful transition to conversion therapy following combination therapy with atezolizumab and bevacizumab in the treatment of unresectable hepatocellular carcinoma (HCC). METHODS: In total, 188 patients with HCC, who received atezolizumab plus bevacizumab combination therapy as the first-line chemotherapy, were studied. Patients who achieved complete response (CR) with systemic chemotherapy alone were excluded. Clinical factors possibly linked to successful transition to conversion therapy and the achievement of cancer-free status were identified. RESULTS: Fifteen (8.0%) patients underwent conversion therapy. In the conversion group, there was a significantly higher proportion of patients with Barcelona Clinic Liver Cancer (BCLC) stage A or B (73.3% versus [vs.] 45.1%; p = .03) and tended to have lower Child-Pugh scores and alpha-fetoprotein levels. Multivariate analysis revealed that BCLC stage was a predictive factor for the implementation of conversion therapy (A or B; odds ratio 3.7 [95% CI: 1.1-13]; p = .04). Furthermore, 10 (66.7%) patients achieved cancer-free status and exhibited a smaller number of intrahepatic lesions at the start of treatment (3.5 vs. 7; p < .01), and a shorter interval between systemic chemotherapy induction and conversion therapy (131 vs. 404 days; p < .01). In addition, the rate of achieving cancer-free status by undergoing surgical resection or ablation therapy was significantly higher (p = .03). CONCLUSION: BCLC stage was the sole predictive factor for successful transition to conversion therapy when using combination therapy with atezolizumab and bevacizumab to treat HCC. Furthermore, a small number of intrahepatic lesions and early transition to conversion therapy were associated with the achievement of cancer-free status.
13
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · New England Journal of Medicine · 2020 · 7.2K citations · Full text
Medicine, Oncology, Pharmacotherapy +12
Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda et al. · Gut · 2019 · 723 citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Zhenwei Peng, Wenzhe Fan, Bowen Zhu et al. · Journal of Clinical Oncology · 2022 · 436 citations
Medicine, Oncology, Pharmacotherapy +10
Tatsuya Yamashita, Masatoshi Kudo, Kenji Ikeda et al. · Journal of Gastroenterology · 2019 · 227 citations · Full text
Medicine, Oncology, Pharmacotherapy +13